Premium
Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β‐thalassaemia: results from the ESCALATOR study
Author(s) -
Taher Ali,
Elalfy Mohsen S.,
Al Zir Kusai,
Daar Shahina,
Al Jefri Abdullah,
Habr Dany,
KriemlerKrahn Ulrike,
Roubert Bernard,
ElBeshlawy Amal
Publication year - 2011
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2011.01661.x
Subject(s) - deferasirox , medicine , deferiprone , intensive care medicine , deferoxamine , pediatrics , thalassemia
This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron‐overloaded patients with β‐thalassaemia from the ESCALATOR trial ( n = 231). Mean liver iron concentrations (LIC) decreased significantly from 21.1 ± 8.2 to 14.2 ± 12.1 mg Fe/g dry weight (dw) at 2 yr ( P < 0.001) in patients with LIC ≥7 mg Fe/g dw at baseline; patients with LIC <7 mg Fe/g dw maintained these levels over the treatment period. The proportion of patients with LIC <7 mg Fe/g dw increased from 9.4% at core baseline to 39.3% by the end of year 2. The results showed that deferasirox enabled therapeutic goals to be achieved, by maintaining LIC in patients with LIC <7 mg Fe/g dw at a mean dose of 22.4 ± 5.2 mg/kg/d and significantly reducing LIC in patients with LIC ≥7 mg Fe/g dw at a mean dose of 25.7 ± 4.2 mg/kg/d, along with a manageable safety profile.